Author: digi

Case Studies: Packaging Failures in Real-World Stability Testing

In pharmaceutical manufacturing, packaging failures during stability testing can result in compromised product quality, regulatory citations, or delayed approvals. These failures often stem from overlooked container-closure risks, inadequate validation, or environmental stress. This article presents real-world case studies where packaging systems failed during stability and offers practical lessons to help you prevent similar outcomes. Case…

Packaging and Containers, Pharmaceutical Containers and Closures for Stability

SOP for Addressing Stability Testing for Drugs under Expedited Approval Pathways

SOP for Addressing Stability Testing for Drugs under Expedited Approval Pathways Procedure for Stability Testing of Drugs Under Expedited Approval Pathways 1) Purpose The purpose of this SOP is to define a procedure for conducting stability testing for drugs under expedited approval pathways, ensuring compliance with regulatory requirements while maintaining product quality, safety, and efficacy….

Stability Studies SOP

Avoid Retesting Without QA-Approved Justification in Stability Studies

Understanding the Tip: Why retesting stability samples needs strict control: Stability testing must reflect real-time degradation trends and provide a reliable basis for shelf life. Retesting without proper authorization can obscure true data, delay investigations, or result in selective reporting. Only when scientifically justified and QA-approved should a retest be allowed. This practice upholds the…

Stability Study Tips

How to Justify Study Continuation After Chamber Deviations

Stability chambers are central to the accurate assessment of pharmaceutical product shelf life. However, unplanned deviations—such as temperature or humidity excursions—can occur, threatening data integrity. When such events arise, pharmaceutical professionals must determine whether the study can continue and how to justify this decision to regulatory bodies. 🔍 Understanding the Impact of Chamber Deviations Deviations…

Equipment and Calibration, Impact of Equipment Deviations on Stability Data

Comparing Glass vs. Plastic for Long-Term Storage in Pharma

The choice between glass and plastic containers significantly influences the stability, quality, and regulatory acceptability of pharmaceutical products. Each material has its advantages and limitations, particularly when used for long-term storage. This tutorial compares the two in terms of chemical compatibility, permeability, safety, sustainability, and compliance—helping pharma professionals make informed packaging decisions. Material Overview: Properties…

Packaging and Containers, Pharmaceutical Containers and Closures for Stability

Common Regulatory Pitfalls in Container Selection

Container selection may seem straightforward, but it is a frequent source of regulatory observations and approval delays in pharmaceutical development. Regulatory agencies expect a risk-based, well-documented approach to container closure system (CCS) selection, especially for stability testing. This article highlights the most common regulatory pitfalls and how to avoid them when selecting containers for your…

Packaging and Containers, Pharmaceutical Containers and Closures for Stability

Understanding Critical vs. Non-Critical Deviations in Stability Equipment

In the pharmaceutical industry, especially within GMP environments, equipment deviations can severely impact the validity of stability studies. Regulatory agencies such as the USFDA or EMA require documented evidence of deviation classifications and associated risk assessments. This tutorial explores the core differences between critical and non-critical deviations in stability equipment and offers a practical roadmap…

Equipment and Calibration, Impact of Equipment Deviations on Stability Data

GMP Requirements for Container Closure Documentation in Stability Studies

Container closures are critical components in pharmaceutical packaging, especially when conducting stability studies. Regulatory agencies expect comprehensive and traceable documentation of container closure systems (CCS) to ensure product quality, safety, and data reliability. This tutorial explains the key GMP documentation requirements for closures in the context of stability testing. Importance of Documenting Container Closure Details…

Packaging and Containers, Pharmaceutical Containers and Closures for Stability

Include Specific Degradation Markers for Peptides and Proteins in Stability Studies

Understanding the Tip: Why degradation markers are crucial for biologic drug stability: Unlike small molecules, peptides and proteins are susceptible to a range of complex degradation pathways. Common mechanisms such as deamidation, oxidation, disulfide scrambling, and aggregation can lead to loss of activity, increased immunogenicity, or changes in pharmacokinetics. Generic physical or chemical tests may…

Stability Study Tips

Best Practices in Container Closure Selection for Stability Testing

In stability testing, the container closure system (CCS) acts as a critical barrier against environmental threats that can degrade pharmaceutical products. Poor closure selection can result in integrity failures, compromised drug quality, or regulatory setbacks. This article outlines best practices for selecting appropriate container closures that support robust and compliant stability study outcomes. 💡 Understand…

Packaging and Containers, Pharmaceutical Containers and Closures for Stability